The in¯uence of pregnancy in multiple sclerosis has been a matter of controversy for a long time. The Pregnancy in Multiple Sclerosis (PRIMS) study was the ®rst large prospective study which aimed to assess the possible in¯uence of pregnancy and delivery on the clinical course of multiple sclerosis. We report here the 2-year post-partum follow-up and an analysis of clinical factors which might predict the likelihood of a relapse in the 3 months after delivery. The relapse rate in each trimester up to the end of the second year post-partum was compared with that in the pre-pregnancy year. Clinical predictors of the presence or absence of a postpartum relapse were analysed by logistic regression analysis. Using the best multivariate model, women were classi®ed as having or not having a post-partum relapse predicted, and this was compared with the observed outcome. The results showed that, compared with the pre-pregnancy year, there was a reduction in the relapse rate during pregnancy, most marked in the third trimester, and a marked increase in the ®rst 3 months after delivery. Thereafter, from the second trimester onwards and for the following 21 months, the annualized relapse rate fell slightly but did not differ signi®cantly from the relapse rate recorded in the pre-pregnancy year. Despite the increased risk for the 3 months post-partum, 72% of the women did not experience any relapse during this period. Con®rmed disability continued to progress steadily during the study period. Three indices, an increased relapse rate in the pre-pregnancy year, an increased relapse rate during pregnancy and a higher DSS (Kurtzke's Disability Status Scale) score at pregnancy onset, signi®cantly correlated with the occurrence of a postpartum relapse. Neither epidural analgesia nor breastfeeding was predictive. When comparing the predicted and observed status, however, only 72% of the women were correctly classi®ed by the multivariate model. In conclusion, the results for the second year post-partum con®rm that the relapse rate remains similar to that of the pre-pregnancy year, after an increase in the ®rst trimester following delivery. Women with greater disease activity in the year before pregnancy and during pregnancy have a higher risk of relapse in the postpartum 3 months. This is, however, not suf®cient to identify in advance women with multiple sclerosis who are more likely to relapse, especially for planning therapeutic trials aiming to prevent post-partum relapses.
Summary
The in¯uence of pregnancy in multiple sclerosis has been a matter of controversy for a long time. The Pregnancy in Multiple Sclerosis (PRIMS) study was the ®rst large prospective study which aimed to assess the possible in¯uence of pregnancy and delivery on the clinical course of multiple sclerosis. We report here the 2-year post-partum follow-up and an analysis of clinical factors which might predict the likelihood of a relapse in the 3 months after delivery. The relapse rate in each trimester up to the end of the second year post-partum was compared with that in the pre-pregnancy year. Clinical predictors of the presence or absence of a postpartum relapse were analysed by logistic regression analysis. Using the best multivariate model, women were classi®ed as having or not having a post-partum relapse predicted, and this was compared with the observed outcome. The results showed that, compared with the pre-pregnancy year, there was a reduction in the relapse rate during pregnancy, most marked in the third trimester, and a marked increase in the ®rst 3 months after delivery. Thereafter, from the second trimester onwards and for the following 21 months, the annualized relapse rate fell slightly but did not differ signi®cantly from the relapse rate recorded in the pre-pregnancy year. Despite the increased risk for the 3 months post-partum, 72% of the women did not experience any relapse during this period. Con®rmed disability continued to progress steadily during the study period. Three indices, an increased relapse rate in the pre-pregnancy year, an increased relapse rate during pregnancy and a higher DSS (Kurtzke's Disability Status Scale) score at pregnancy onset, signi®cantly correlated with the occurrence of a postpartum relapse. Neither epidural analgesia nor breastfeeding was predictive. When comparing the predicted and observed status, however, only 72% of the women were correctly classi®ed by the multivariate model. In conclusion, the results for the second year post-partum con®rm that the relapse rate remains similar to that of the pre-pregnancy year, after an increase in the ®rst trimester following delivery. Women with greater disease activity in the year before pregnancy and during pregnancy have a higher risk of relapse in the postpartum 3 months. This is, however, not suf®cient to identify in advance women with multiple sclerosis who are more likely to relapse, especially for planning therapeutic trials aiming to prevent post-partum relapses.
Introduction
The in¯uence of pregnancy in multiple sclerosis has been a matter of controversy for a long time. For many years, women with multiple sclerosis were discouraged from contemplating pregnancy (Douglass and Jorgensen, 1948; Tillman, 1950; Sweeney, 1953; Hutchinson, 1993; Sadovnick et al., 1994; Rudick, 1995) due to the possible deleterious effect of pregnancy on multiple sclerosis. Moreover, the pattern of progression of neurological disability over the years can affect family planning (Korn-Lubetzki et al., 1984) . KornLubetzki and colleagues found, in a large retrospective study, that the frequency of relapses of multiple sclerosis decreased during pregnancy, increased in the immediate post-partum period and was similar to the frequency observed out of pregnancy when considering the pregnancy year (9 months of pregnancy and the ®rst 3 months post-partum).
The Pregnancy in Multiple Sclerosis (PRIMS) study was the ®rst large prospective study of the natural history of multiple sclerosis in pregnant women (Confavreux et al., 1998) . This observational, European, multicentre study aimed to assess the in¯uence of pregnancy and delivery on the clinical course of multiple sclerosis and showed a signi®cant decline in the relapse rate during pregnancy, most marked in the third trimester, with a rebound increase in the ®rst 3 months post-partum. There was no apparent acceleration of disability during the puerperium and neither breast-feeding nor epidural analgesia had any speci®c adverse effect.
The PRIMS study participants continued to collect data on the cohort of 227 women who had a pregnancy with a live infant, for a total of up to 2 years post-partum, as initially designed in the protocol. A further analysis was performed of putative clinical predictors which might identify women who were more likely to relapse after delivery and which might be useful to the neurologist advising a pregnant woman with multiple sclerosis regarding prophylactic therapies.
The aims of this paper are to report the 2-year post-partum follow-up and to analyse the factors predictive of relapse in the 3 months after delivery.
Patients and methods
The study population consisted of 227 women who had fullterm delivery of a live infant and who had multiple sclerosis for at least 1 year prior to conception. If a woman had been followed in the PRIMS study for more than one pregnancy, only the ®rst one was considered for analysis. Details of methods can be found in the previous report (Confavreux et al., 1998) . The diagnosis of multiple sclerosis was classi®ed according to Poser's criteria (Poser et al., 1983) . A relapse of multiple sclerosis was de®ned as the appearance, reappearance or worsening of symptoms of neurological dysfunction lasting >24 h. Fatigue alone was not considered as a relapse. Disability was assessed with Kurtzke's Disability Status Scale (DSS) (Kurtzke, 1961) , which is based on data from the neurological examination and the patient's ability to walk. Scores range from 0 (no abnormality) to 10 (death caused by multiple sclerosis). Con®rmed neurological disability was de®ned as the minimal level of persistent disability recorded on two consecutive examinations at least 3 months apart, excluding any transient worsening of disability related to relapses.
All women had been pregnant for at least 4 weeks but <36 weeks at entry into the study. Using the European Database for Multiple Sclerosis (EDMUS) system (Confavreux et al., 1992) , the data were analysed at the EDMUS Coordinating Centre in Lyon, France. The ethics committee of St Vincent's University Hospital, Dublin, Ireland, approved the study protocol and the women gave informed consent. Demographic data and data on the course of multiple sclerosis prior to entry into the study were recorded and patients were examined at 20, 28 and 36 weeks of gestation and 3, 6 12, 18 and 24 months post-partum. Telephone assessments were made at 40 weeks of gestation and 1, 9, 15 and 21 months post-partum. The DSS was assessed retrospectively 1 year prior to pregnancy and at the beginning of the pregnancy, and prospectively at entry to the study, at 36 weeks of gestation, and 3, 6, 12, 18 and 24 months postpartum. Epidural analgesia and breast-feeding were recorded.
The relapse rates per woman per year during each 3-month period during pregnancy and the 2 years post-partum were compared with the relapse rate during the year before pregnancy by means of paired, two-sided t-tests.
The effects of epidural analgesia and breast-feeding on the course of multiple sclerosis were analysed by univariate logistic regression, as were other clinical variables thought to be related to the presence or absence of a relapse in the ®rst trimester after delivery. These variables were also tested in different multivariate logistic models. Women were then classi®ed according to the results of the best model, with a cut-off value of 0.5, as having a post-partum relapse predicted or not, and compared with the observed status. All statistical analyses were performed with SPSS for Windows software version 10.1 (SPSS, 2001).
Results

Data collection
Seventy six per cent of the 227 women were known to their neurologist before entry to the study. Forty two per cent entered the study in the ®rst trimester, 43% in the second trimester and 15% in the third trimester of pregnancy. The follow-up was at least 6 months post-partum in 216 women (95.2%), 12 months in 201 (88.5%), 18 months in 182 (80.2%) and 24 months in 163 women (71.8%). Data on epidural analgesia and breast-feeding were available in 222 and 210 women respectively. Out of these, 42 women (18.9%) chose to have epidural analgesia and 124 (54.6%) to breast-feed their child.
Only ®ve patients received disease-modifying drugs in the 6 months after delivery (four azathioprine and one mitoxantrone) and eleven in the second 6-month period (three azathioprine, six interferon b 1 b, one mitoxantrone and one cyclophosphamide). Data on immunoactive treatments in the second year post-partum are not available, as they were not mandatory in the study protocol.
Relapse rate
The annualized relapse rate for each 3-month period is given in Table 1 and Fig. 1 . As previously reported, in comparison with the pre-pregnancy year, in which the mean T SD relapse rate was 0.7 T 0.9, there was a reduction of the relapse rate during pregnancy, most marked in the third trimester (0.2 T 0.9, P < 0.001), with a marked increase in the ®rst 3 months after delivery (1.2 T 2.0, P < 0.001). Thereafter, from the second post-partum trimester onwards and for the following 21 months, the annualized relapse rate fell slightly but did not differ signi®cantly from the annualized relapse rate recorded in the pre-pregnancy year. Despite the clear increased risk of relapse in the post-partum 3 months, 160 women (72%) did not experience any relapse during this period.
The annualized relapse rate of the pregnancy year, de®ned as encompassing the nine months of pregnancy and the ®rst 3-month period after delivery, was similar (0.6 T 0.8) to that of the pre-pregnancy year.
Con®rmed disability
Con®rmed disability progressed steadily during the whole study period. Pregnancy, delivery and post-partum did not seem to have any effect on disability progression (Fig. 2) .
Indicators of the occurrence of a relapse in the ®rst 3-month period after delivery
The distribution of women according to the presence or absence of a relapse in the year before pregnancy, during pregnancy and in the ®rst 3 months after delivery is reported in Fig. 3 . The likelihood of having at least one relapse during the ®rst 3 months post-partum according to demographic and disease-related factors was estimated by a logistic regression analysis (Table 2) . Only three factors signi®cantly correlated with the presence of a post-partum relapse. There was a 1.7-fold increased risk with each relapse experienced during the pre-pregnancy year and 1.8-fold increased risk for each relapse during pregnancy (P < 0.002 and 0.02 respectively). Patients who had a higher DSS at pregnancy onset were also more likely to have a post-partum relapse (odds ratio = 1.3, P = 0.04). The occurrence of a post-partum relapse was not related to breast-feeding, epidural analgesia, age at multiple sclerosis onset, age at pregnancy onset, disease duration, total number of relapses before pregnancy, number of previous pregnancies or child gender. All the variables were examined in the multivariate analysis, whatever the result of the univariate analysis. In the best multivariate model, only the number of relapses in the pre-pregnancy year, the number of relapses during pregnancy and disease duration at pregnancy onset correlated independently with the presence of a post-partum relapse (Table 3 ). The area under the ROC curve corresponding to this multivariate analysis was 0.72, which is considered to be acceptable discrimination. This mathematical model makes it possible to classify women according to their baseline characteristics, in relation to the probability of experiencing a relapse in the ®rst trimester after delivery. The model predicted a relapse for only 16 (7%) of the 223 women, but eight of these women did not relapse in the ®rst 3 months post-partum. By contrast, out of 207 women for which it predicted no relapse, 55 (27%) actually relapsed in the postpartum period. When comparing the predicted and observed status, only 160 out of 223 (72%) of the women were correctly classi®ed by this model and 63 out of 223 (28%) were misclassi®ed (Fig. 4) .
Discussion
The PRIMS study affords a unique opportunity to improve our knowledge on interactions between pregnancy and multiple sclerosis. With 227 pregnant women with multiple sclerosis and a full-term delivery of a life infant, from 12 European countries, followed prospectively during pregnancy and up to the end of the second year post-partum, this is the largest natural history study ever conducted in this setting.
The study population can be considered as representative of women with multiple sclerosis contemplating childbearing: they were young, with a mean age of 30 years at pregnancy onset, and had a relapsing±remitting disease with mild disability (mean DSS 1.3). The mean relapse rate in the year before pregnancy was 0.7, very similar to the relapse rate observed in natural history studies for this early stage of the disease (Confavreux et al., 1998) . Therefore, a selection bias is unlikely. However, the validity of pre-pregnancy data can be questioned, as the study formally started when the women were pregnant. In fact, 76% of the women were known to their neurologist before the study and 52% of the women had been followed prospectively by the participating neurologists before the study. This reduces the probability of recall bias. Sixty four (28%) women were lost to follow-up before the end of the second year post-partum, as they did not return to their neurologist at the scheduled visits. There were no differences between the women who were followed and those lost to follow-up with respect to demographic and clinical data (DSS scores and relapses before pregnancy, during pregnancy and in the ®rst trimester post-partum), and no differences in the frequency of breast-feeding and epidural analgesia. Excluding women lost to follow-up from the analyses should therefore not have introduced any systematic error.
As previously reported (Confavreux et al., 1998) , the relapse rate decreased signi®cantly during pregnancy, especially in the third trimester, and increased in the ®rst trimester after delivery. From the second trimester onwards, in the 2 years post-partum, the relapse rate did not differ from that in Fig. 1 Annualized relapse rate in the year before pregnancy, during pregnancy and in the two years after delivery among 227 women with MS (vertical bars represent means and 95% con®dence intervals). Fig. 3 Flow-chart of patients regarding the presence or absence of one or more relapses in the pre-pregnancy year, during pregnancy and in the 3-month period after delivery among 227 women with multiple sclerosis. the pre-pregnancy year. We cannot exclude the possibility that minor relapses could have been not recorded during the pre-study period, but the bias introduced in this way would have underestimated the true reduction in the relapse rate during pregnancy. Con®rmed disability seemed not to be in¯uenced by pregnancy, delivery and the post-partum period. With the addition of data for the second year postpartum, the follow-up is now long enough to exclude a pregnancy-related increase in con®rmed disability that could not have been detected at 1 year. Again, the validity of the pre-pregnancy data can be questioned. As stated above, a majority of the women were already known by their neurologist before their enrolment in the study. It could also be questioned whether treatments that were potentially introduced after delivery could have had an impact on these ®ndings. Only ®ve patients received a disease-modifying drug in the ®rst 6 months post-partum and 11 in the second 6-month period. In the ®rst year, when assessment regarding treatments was reliable and complete, the number of treated patients was small and should not have changed the overall results for this period. Regarding the second year postpartum, we have no data on immunoactive treatments as the study had not been designed to collect them. In this second year, immunoactive treatment may have reduced the relapse rate, but the length of the treatment period was too short for us to expect a signi®cant change in the measure of con®rmed disability.
Neither breast-feeding nor epidural analgesia seem to have any effect on relapses and disability, with the proviso that the study was not designed to assess this risk. Multivariate logistic regression analysis among 223 women with multiple sclerosis. CI = con®dence interval; MS = multiple sclerosis. The following formula can be used to calculate the individual probability (Pr) of having a relapse during the three months post-partum = In Figure 4 , with a cut-off limit of 0.50, a women is supposed to have a relapse if her probability is higher than 0.50. In this respect, it is important to note a possible misunderstanding. Women who chose to breast-feed experienced fewer relapses and had milder disability scores in the year before and during pregnancy, in comparison with women who chose not to breast-feed (Confavreux et al., 1998) . In an editorial accompanying the original report, Whitaker (Whitaker, 1998) suggested that`the ®nding¼ that breastfeeding had a bene®cial effect by reducing relapses during the course of the study is unexpected'. The interpretation of the data on breast-feeding by the PRIMS study group is that multiple sclerosis patients who chose to breast-feed had a milder form of multiple sclerosis from the beginning of the study period, 12 months before conception, and that patients with more active disease decided not to breast-feed. It cannot be concluded from our data that breast-feeding has a protective effect per se on disease activity in the post-partum period.
The relapse rate over the period from month 4 to month 24 post-partum did not differ signi®cantly from the relapse rate in the pre-pregnancy year. Thus, the period of increased risk of relapse relates only to the ®rst 3 months after delivery. While clearly this is a period of high risk, only 28% of the cohort had a relapse during this time. Two factors appeared predictive of an increased likelihood of a relapse in the 3 months post-partum: the number of relapses in the year before pregnancy and the number of relapses during pregnancy. The DSS score at pregnancy onset just reached the signi®cance level in the univariate analysis, but was not independently correlated to the presence of a post-partum relapse as it did not remain signi®cant in the multivariate analysis. Surprisingly, the higher the DSS score, the higher the risk of relapse. One should, however, consider that this analysis was done in patients who had low disability scores, with a mean of 1.3, and that results should not be extended to patients with higher DSS scores. By contrast, multiple sclerosis duration added some information in the multivariate model even if it was not signi®cant alone: the longer the multiple sclerosis duration, the higher the likelihood of a relapse. Other disease or pregnancy indices were not related to the presence or absence of the post-partum relapse.
The more active the disease in the pre-pregnancy year and during pregnancy, the higher the risk of relapse in the postpartum period. However, of 33 women who had had at least one relapse in each period (pre-pregnancy year and pregnancy) and who were followed at least until the end of the ®rst trimester after delivery, 20 (61%) did not relapse in the ®rst trimester after delivery. By contrast, 14 (16%) of the 87 women without any relapse in these periods experienced at least one relapse after delivery. Moreover, the risk of having a relapse in the ®rst trimester after delivery could not be reliably predicted even by the mathematical models for a given individual. In the best proposed multivariate model, 28% of the women were misclassi®ed. In other words, if, by using the multivariate model, patients were chosen for a putative post-partum therapy to prevent relapses, then eight of 16 patients in whom a relapse was predicted would have been treated needlessly. Similarly, of the 207 women predicted by this model not to relapse, 55 who actually experienced a relapse would not have been treated. However, depending on the choice of the treating physician and the patient to over-or undertreat, it is possible to modify this ®gure by changing the cut-off limit in the same model. These results have clear consequences for planning future therapeutic trials aiming to prevent post-partum relapses. There is no clinical tool for identifying with certainty in advance the women with multiple sclerosis who will eventually experience a relapse in the ®rst 3 months post-partum. Fig. 4 Individual prediction of the presence or absence of a relapse in the 3-month period after delivery among 223 women with multiple sclerosis, according to the best multivariate model.
